Immuno-Imaging to Predict Treatment Response in Infection, Inflammation and Oncology
Abstract
:1. Introduction
1.1. Infectious Diseases
1.2. Inflammatory Diseases
2. Radiolabelled White Blood Cell Scintigraphy for the Diagnosis of Osteomyelitis (OM) and Therapy Follow-Up
3. (18F)-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography ((18F)-FDG-PET/CT) for Imaging and Monitoring Therapy of Fungal Infections
4. Radiolabelled Somatostatin Analogues in Rheumatoid Arthritis
5. Radiolabelled Anti-CD20 and Anti-Tumor Necrosis Factor (Anti-TNFα) Monoclonal Antibodies in Rheumatoid Arthritis
5.1. (99mTc)-Infliximab Scintigraphy
5.2. 99mTc Radiolabelled Adalimumab Scintigraphy
5.3. 99mTc-Rituximab Scintigraphy
5.4. 99mTc Radiolabelled Certolizumab Pegol Scintigraphy
6. 18F-FDG-PET/CT to Image Large Vessel Vasculitis
6.1. Diagnosis, Extent and Impact of (18F)-FDG-PET/CT on the Management of Large Vessel Vasculitis (LVV)
6.2. Role of (18F)-FDG-PET/CT in Monitoring the Treatment Response in LVV
7. Imaging Immunological Network in Cancer
7.1. Programmed Cell Death Protein (PD-1) Imaging
7.2. Programmed Cell Death Protein Ligand 1 (PD-L1) Imaging
7.3. CTLA-4 Imaging
7.4. CD25 as Target for Imaging Tumour-Infiltrating Lymphocytes
7.5. Evaluation or Response to Immunotherapy
8. Conclusions
Author Contributions
Acknowledgments
Conflicts of Interest
References
- Signore, A.; Anzola, K.L.; Auletta, S.; Varani, M.; Petitti, A.; Pacilio, M.; Galli, F.; Lauri, C. Current status of molecular imaging in inflammatory disorders. Curr. Pharm. Des. 2018, 24, 743–753. [Google Scholar] [CrossRef] [PubMed]
- Glaudemans, A.W.; Prandini, N.; Di Girolamo, M.; Argento, G.; Lauri, C.; Lazzeri, E.; Muto, M.; Sconfienza, L.M.; Signore, A. Hybrid imaging of musculoskeletal infections. Q. J. Nucl. Med. Mol. Imaging 2018, 62, 3–13. [Google Scholar] [PubMed]
- Chianelli, M.; Boerman, O.C.; Malviya, G.; Galli, F.; Oyen, W.J.; Signore, A. Receptor binding ligands to image infection. Curr. Pharm. Des. 2008, 14, 3316–3325. [Google Scholar] [CrossRef] [PubMed]
- Ruf, J.; Oeser, C.; Amthauer, H. Clinical role of anti-granulocyte MoAb versus radiolabeled white blood cells. Q. J. Nucl. Med. Mol. Imaging 2010, 54, 599–616. [Google Scholar]
- Malherbe, C.; Dupont, A.C.; Maia, S.; Venel, Y.; Erra, B.; Santiago-Ribeiro, M.J.; Arlicot, N. Estimation of the added value of 99mTc-HMPAO labelled white blood cells scintigraphy for the diagnosis of infectious foci. Q. J. Nucl. Med. Mol. Imaging 2017, 61. [Google Scholar] [CrossRef]
- Glaudemans, A.W.; de Vries, E.F.; Galli, F.; Dierckx, R.A.; Slart, R.H.; Signore, A. The use of (18)F-FDG-PET/CT for diagnosis and treatment monitoring of inflammatory and infectious diseases. Clin. Dev. Immunol. 2013, 2013, 623036. [Google Scholar] [CrossRef] [PubMed]
- Auletta, S.; Galli, F.; Lauri, C.; Martinelli, D.; Santino, I.; Signore, A. Imaging bacteria with radiolabelled quinolones, cephalosporins and siderophores for imaging infection: A systematic review. Clin. Transl. Imaging 2016, 4, 229–252. [Google Scholar] [CrossRef] [PubMed]
- Agrawal, S.G.; Mather, S.J. Pathogen identification by nuclear imaging—almost there? Eur. J. Nucl. Med. Mol. Imaging 2012, 39, 1173–1174. [Google Scholar] [CrossRef]
- Buursma, A.R.; Rutgers, V.; Hospers, G.A.; Mulder, N.H.; Vaalburg, W.; de Vries, E.F. 18F-FEAU as a radiotracer for herpes simplex virus thymidine kinase gene expression: In-vitro comparison with other PET tracers. Nucl. Med. Commun. 2006, 27, 25–30. [Google Scholar] [CrossRef]
- Di Gialleonardo, V.; Signore, A.; Glaudemans, A.W.; Dierckx, R.A.; de Vries, E.F. N-(4-18F-fluorobenzoyl)interleukin-2 for PET of human-activated T lymphocytes. J. Nucl. Med. 2012, 53, 679–686. [Google Scholar] [CrossRef] [PubMed]
- D’Alessandria, C.; di Gialleonardo, V.; Chianelli, M.; Mather, S.J.; de Vries, E.F.; Scopinaro, F.; Dierck, R.A.; Signore, A. Synthesis and optimization of the labelling procedure of 99mTc-HYNIC-interleukin-2 for in vivo imaging of activated T lymphocytes. Mol. Imaging. Biol. 2010, 12, 539–546. [Google Scholar] [CrossRef]
- Chianelli, M.; Parisella, M.G.; Visalli, N.; Mather, S.J.; D’Alessandria, C.; Pozzilli, P.; Signore, A. IMDIAB study group. Pancreatic scintigraphy with 99mTc-interleukin-2 at diagnosis of type 1 diabetes and after 1 year of nicotinamide therapy. Diabetes Metab. Res. Rev. 2008, 24, 115–122. [Google Scholar] [CrossRef]
- Annovazzi, A.; Biancone, L.; Caviglia, R.; Chianelli, M.; Capriotti, G.; Mather, S.J.; Caprilli, R.; Pallone, F.; Scopinaro, F.; Signore, A. 99mTc-interleukin-2 and (99m)Tc-HMPAO granulocyte scintigraphy in patients with inactive Crohn’s disease. Eur. J. Nucl. Med. Mol. Imaging 2003, 30, 374–382. [Google Scholar] [CrossRef] [PubMed]
- Signore, A.; Chianelli, M.; Ronga, G.; Pozzilli, P.; Beverley, P.C. In vivo labelling of activated T lymphocytes by i.v. injection of 123I-IL2 for detection of insulitis in type 1 diabetes. Prog. Clin. Biol. Res. 1990, 355, 229–238. [Google Scholar]
- Vanhagen, P.M.; Markusse, H.M.; Lamberts, S.W.; Kwekkeboom, D.J.; Reubi, J.C.; Krenning, E.P. Somatostatin receptor imaging. The presence of somatostatin receptors in rheumatoid arthritis. Arthritis Rheum. 1994, 37, 1521–1527. [Google Scholar] [CrossRef] [PubMed]
- Horton, S.C.; Emery, P. Biological therapy for rheumatoid arthritis: Where are we now? Br. J. Hosp. Med. 2012, 73, 12–18. [Google Scholar] [CrossRef]
- Conti, F.; Ceccarelli, F.; Priori, R.; Iagnocco, A.; Signore, A.; Valesini, G. Intra-articular infliximab in patients with rheumatoid arthritis and psoriatic arthritis with monoarthritis resistant to local glucocorticoids. Clinical efficacy extended to patients on systemic anti-tumour necrosis factor alpha. Ann. Rheum. Dis. 2008, 67, 1787–1790. [Google Scholar] [CrossRef]
- Malviya, G.; Anzola, K.L.; Podestà, E.; Laganà, B.; Del Mastro, C.; Dierckx, R.A.; Scopinaro, F.; Signore, A. (99m)Tc-labeled rituximab for imaging B lymphocyte infiltration in inflammatory autoimmune disease patients. Mol. Imaging Biol. 2012, 14, 637–646. [Google Scholar] [CrossRef] [PubMed]
- Iodice, V.; Laganà, B.; Lauri, C.; Capriotti, G.; Germano, V.; D’Amelio, R.; Picchianti Diamanti, A. Imaging B lymphocytes in autoimmune inflammatory diseases. Q. J. Nucl. Med. Mol. Imaging 2014, 58, 258–268. [Google Scholar] [PubMed]
- Malviya, G.; Signore, A.; Laganà, B.; Dierckx, R.A. Radiolabelled peptides and monoclonal antibodies for therapy decision making in inflammatory diseases. Curr. Pharm. Des. 2008, 14, 2401–2414. [Google Scholar] [CrossRef] [PubMed]
- Tiemann, A.H.; Hofmann, G.O. Principles of the therapy of bone infections in adult extremities: Are there any new developments? Strateg. Trauma Limb. Reconstr. 2009, 4, 57–64. [Google Scholar] [CrossRef] [PubMed]
- Jutte, P.; Lazzeri, E.; Sconfienza, L.M.; Cassar-Pullicino, V.; Trampuz, A.; Petrosillo, N.; Signore, A. Diagnostic flowcharts in osteomyelitis, spondylodiscitis and prosthetic joint infection. Q. J. Nucl. Med. Mol. Imaging 2014, 58, 2–19. [Google Scholar]
- Lew, D.P.; Waldvogel, F.A. Osteomyelitis. Lancet 2004, 364, 369–379. [Google Scholar] [CrossRef]
- Palestro, C.J. Radionuclide imaging of osteomyelitis. Semin. Nucl. Med. 2015, 45, 32–46. [Google Scholar] [CrossRef] [PubMed]
- Signore, A.; Lauri, C.; Galli, F. Radiolabelled probes targeting infection and inflammation for personalized medicine. Curr. Pharm. Des. 2014, 20, 2338–2345. [Google Scholar] [CrossRef] [PubMed]
- Erba, P.A.; Glaudemans, A.W.; Veltman, N.C.; Sollini, M.; Pacilio, M.; Galli, F.; Dierckx, R.A.; Signore, A. Image acquisition and interpretation criteria for 99mTc-HMPAO-labelled white blood cell scintigraphy: Results of a multicentre study. Eur. J. Nucl. Med. Mol. Imaging 2014, 41, 615–623. [Google Scholar] [CrossRef] [PubMed]
- Glaudemans, A.W.; de Vries, E.F.; Vermeulen, L.E.; Slart, R.H.; Dierckx, R.A.; Signore, A. A large retrospective single-centre study to define the best image acquisition protocols and interpretation criteria for white blood cell scintigraphy with 99mTc-HMPAO-labelled leucocytes in musculoskeletal infections. Eur. J. Nucl. Med. Mol. Imaging 2013, 40, 1760–1769. [Google Scholar] [CrossRef] [PubMed]
- Roca, M.; de Vries, E.F.; Jamar, F.; Israel, O.; Signore, A. Guidelines for the labelling of leucocytes with (111)In-oxine. Inflammation/Infection Taskgroup of the European Association of Nuclear Medicine. Eur. J. Nucl. Med. Mol. Imaging 2010, 37, 835–841. [Google Scholar] [CrossRef] [PubMed]
- De Vries, E.F.; Roca, M.; Jamar, F.; Israel, O.; Signore, A. Guidelines for the labelling of leucocytes with (99m)Tc-HMPAO. Inflammation/Infection Taskgroup of the European Association of Nuclear Medicine. Eur. J. Nucl. Med. Mol. Imaging 2010, 37, 842–848. [Google Scholar] [CrossRef] [PubMed]
- Signore, A.; Jamar, F.; Israel, O.; Buscombe, J.; Martin-Comin, J.; Lazzeri, E. Clinical indications, image acquisition and data interpretation for white blood cells and anti-granulocyte monoclonal antibody scintigraphy: An EANM procedural guideline. Eur. J. Nucl. Med. Mol. Imaging 2018, 45, 1816–1831. [Google Scholar] [CrossRef]
- Signore, A.; Glaudemans, A.W. The molecular imaging approach to image infections and inflammation by nuclear medicine techniques. Ann. Nucl. Med. 2011, 25, 681–700. [Google Scholar] [CrossRef] [PubMed]
- Signore, A. Techniques, image acquisition and interpretation criteria. In Diagnostic Imaging of Infections and Inflammatory Diseases: A Multidisciplinary Approach; Signore, A., Quintero, A.M., Eds.; Wiley: Hoboken, NJ, USA, 2013; pp. 147–167. [Google Scholar]
- Glaudemans, A.W.; Galli, F.; Pacilio, M.; Signore, A. Leukocyte and bacteria imaging in prosthetic joint infection. Eur. Cell Mater. 2013, 25, 61–77. [Google Scholar] [CrossRef] [PubMed]
- Palestro, C.; Swyer, A.; Kim, C.; Goldsmith, S. Infected knee prosthesis: Diagnosis with In-111 leukocyte, Tc-99m sulfur colloid, and Tc-99m MDP imaging. Radiology 1991, 179, 645–648. [Google Scholar] [CrossRef] [PubMed]
- Prandini, N.; Lazzeri, E.; Rossi, B.; Erba, P.; Parisella, M.G.; Signore, A. Nuclear medicine imaging of bone infections. Nucl. Med. Commun. 2006, 27, 633–644. [Google Scholar] [CrossRef] [PubMed]
- Lauri, C.; Tamminga, M.; Glaudemans, A.W.J.M.; Juárez Orozco, L.E.; Erba, P.A.; Jutte, P.C.; Lipsky, B.A.; IJzerman, M.J.; Signore, A.; Slart, R.H.J.A. Detection of Osteomyelitis in the Diabetic Foot by Imaging Techniques: A Systematic Review and Meta-analysis Comparing MRI, White Blood Cell Scintigraphy, and FDG-PET. Diabetes Care 2017, 40, 1111–1120. [Google Scholar] [CrossRef] [PubMed]
- Quirce, R.; Carril, J.M.; Gutiérrez-Mendiguchía, C.; Serrano, J.; Rabasa, J.M.; Bernal, J.M. Assessment of the diagnostic capacity of planar scintigraphy and SPECT with 99mTc-HMPAO-labelled leukocytes in superficial and deep sternal infections after median sternotomy. Nucl. Med. Commun. 2002, 23, 453–459. [Google Scholar] [CrossRef]
- Palestro, C.J.; Love, C.; Tronco, G.G.; Tomas, M.B.; Rini, J.N. Combined Labeled Leukocyte and Technetium 99m Sulfur Colloid Bone Marrow Imaging for Diagnosing Musculoskeletal Infection. Radiographics 2006, 26, 859–870. [Google Scholar] [CrossRef]
- Verberne, S.J.; Sonnega, R.J.A.; Temmerman, O.P.P.; Raijmakers, P.G. What is the Accuracy of Nuclear Imaging in the Assessment of Periprosthetic Knee Infection? A Meta-analysis. Clin. Orthop. Relat. Res. 2017, 475, 1395–1410. [Google Scholar] [CrossRef]
- Brammen, L.; Palestro, C.J.; Holinka, J.; Windhager, R.; Sinzinger, H. A retrospective analysis of the accuracy of radioactively labeled autologous leukocytes in patients with infected prosthetic joints. Nucl. Med. Rev. 2017, 20, 81–87. [Google Scholar] [CrossRef]
- Liberatore, M.; Al-Nahhas, A.; Rubello, D. White blood cell scan in the follow-up of infectious diseases: Is the withdrawal of antibiotic therapy necessary? Nucl. Med. Commun. 2007, 28, 151–153. [Google Scholar] [CrossRef]
- Ankrah, O.A.; Sathekge, M.M.; Dierckx, R.A.; Glaudemans, A.W. Imaging fungal infections in children. Clin. Transl. Imaging 2016, 4, 57–72. [Google Scholar] [CrossRef]
- Ankrah, O.A.; Klein, H.C.; Span, L.F.R.; de Vries, E.F.J.; Dierckx, R.A.J.O.; Sathekge, M.M.; Glaudemans, A.W.J.M. The role of PET in monitoring therapy in fungal infections. Curr. Pharm. Des. 2018, 24, 795–805. [Google Scholar] [CrossRef] [PubMed]
- Douglas, A.P.; Thursky, K.A.; Worth, L.J.; Drummond, E.; Hogg, A.; Hicks, R.J.; Slavin, M.A. FDG PET/CT imaging in detecting and guiding management of invasive fungal infections: A retrospective comparison to conventional CT imaging. Eur. J. Nucl. Med. Mol. Imaging 2019, 46, 166–173. [Google Scholar] [CrossRef] [PubMed]
- Leroy-Freschini, B.; Treglia, G.; Argemi, X.; Bund, C.; Kessler, R.; Herbrecht, R.; Imperiale, A. 18F-FDG PET/CT for invasive fungal infection in immunocompromised patients. QJM Int. J. Med. 2018, 111, 613–622. [Google Scholar] [CrossRef]
- Ankrah, O.A.; Span, L.F.R.; Klein, H.C.; de Jong, P.A.; Dierckx, R.A.J.O.; Kwee, T.C.; Sathekge, M.M.; Glaudemans, A.W.J.M. Role of FDG PET/CT in monitoring treatment response in patients with invasive fungal infections. Eur. J. Nucl. Med. Mol. Imaging 2019, 46, 174–183. [Google Scholar] [CrossRef]
- Van del Laken, C.J.; Huisman, M.H.; Voskuyl, A.E. Nuclear imaging of rheumatic diseases. Best Pract. Res. Clin. Rheumatol. 2012, 26, 787–804. [Google Scholar] [CrossRef]
- Wunder, A.; Strau, H.; Gay, S.; Funk, J.; Müller-Ladner, U. Molecular imaging: Novel tools in visualizing rheumatoid arthritis. Rheumatology 2005, 44, 1341–1349. [Google Scholar] [CrossRef] [PubMed]
- Weissleder, R.; Mahmood, U. Molecular imaging. Radiology 2001, 219, 316–333. [Google Scholar] [CrossRef]
- Reubi, J.C.; Waser, B.; Markusse, H.M.; Krenning, E.P.; Vanhagen, M.; Laissue, J.A. Vascular somatostatin receptors in synovium from patients with rheumatoid arthritis. Eur. J. Pharmacol. 1994, 271, 371–378. [Google Scholar] [CrossRef]
- Cascini, G.L.; Cuccurullo, V.; Mansi, L. The non-tumour uptake of 111In-octreotide creates new clinical indications in benign diseases, but also in oncology. Q. J. Nucl. Med. Mol. Imaging 2010, 54, 24–36. [Google Scholar] [PubMed]
- Virgolini, I.; Pangerl, T.; Bischof, C.; Smith-Jones, P.; Peck-Radosavljevic, M. Somatostatine receptor subtype expression in human tissues: A prediction for diagnosis and treatment of cancer. Eur. J. Clin. Investig. 1997, 27, 645–647. [Google Scholar] [CrossRef]
- Takeba, Y.; Suzuki, N.; Takeno, M.; Asai, T.; Tsuboi, S.; Hoshino, T.; Sakane, T. Modulation of synovial cell function by somatostatine in patients with rheumatoid arthritis. Arthritis Rheum. 1997, 40, 2128–2138. [Google Scholar] [CrossRef]
- Anzola, L.K.; Galli, F.; Dierckx, R. Spect radiopharmaceuticals for imaging chronic inflammatory diseases in the last decade. Q. J. Nucl. Med. Mol. Imaging 2015, 59, 197–213. [Google Scholar] [PubMed]
- Roivainen, A.; Jalkanen, S.; Nanni, C. Gallium-labelled peptides for imaging of inflammation. Eur. J. Nucl. Med. Mol. Imaging 2012, 39, S68–S77. [Google Scholar] [CrossRef]
- Anzola, L.K.; Chianelli, M.; Galli, F.; Glaudemans, A.W.J.M.; Martin Martin, L.; Todino, V.; Migliore, A.; Signore, A. Somatostatine receptor scintigraphy in patients with rheumatoid arthritis and secondary Sjögren´s síndrome treated with Infliximab: A pilot study. Eur. J. Nucl. Med. Mol. Imaging Res. 2016, 6, 49. [Google Scholar]
- Roivainen, A.; Parkkola, R.; Yli-Kerttula, T.; Lehikoinen, P.; Viljanen, T.; Mottonen, T.; Nuutila, P.; Minn, H. Use of positron emission tomography with methyl-11C-choline and 2-18F-fluoro-2- deoxy-D-glucose in comparison with magnetic resonance imaging for the assessment of inflammatory proliferation of synovium. Arthritis Rheum. 2003, 48, 3077–3084. [Google Scholar] [CrossRef]
- Beckers, C.; Ribbens, C.; André, B.; Marcelis, S.; Kaye, O.; Mathy, L.; Kaiser, M.J.; Hustinx, R.; Foidart, J.; Malaise, M.G. Assessment of disease activity in rheumatoid arthritis with (18)F-FDG PET. J. Nucl. Med. 2004, 45, 956–964. [Google Scholar]
- Ambrosini, V.; Campana, D.; Bodei, L.; Nanni, C.; Castellucci, P.; Allegri, V.; Montini, G.C.; Tomassetti, P.; Paganelli, G.; Fanti, S. 68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors. J. Nucl. Med. 2010, 51, 669–673. [Google Scholar] [CrossRef] [PubMed]
- Pettinato, C.; Sarnelli, A.; Di Donna, M.; Civollani, S.; Nanni, C.; Montini, G.; Di Pierro, D.; Ferrari, M.; Marengo, M.; Bergamini, C. 68Ga-DOTANOC: Biodistribution and dosimetry in patients affected by neuroendocrine tumors. Eur. J. Nucl. Med. Mol. Imaging 2008, 35, 72–79. [Google Scholar] [CrossRef] [PubMed]
- Ambrosini, V.; Zompatori, M.; De Luca, F.; Antonia, D.; Allegri, V.; Nanni, C.; Malvi, D.; Tonveronachi, E.; Fasano, L.; Fabbri, M.; et al. 68Ga-DOTANOC PET/CT allows somatostatin receptor imaging in idiopathic pulmonary fibrosis: Preliminary results. J. Nucl. Med. 2010, 51, 1950–1955. [Google Scholar] [CrossRef]
- Chianelli, M.; D’Alessandria, C.; Conti, F.; Priori, R.; Valesini, G.; Annovazzi, A.; Signore, A. New radiopharmaceuticals for imaging rheumatoid arthritis. Q. J. Nucl. Med. Mol. Imaging 2006, 50, 217–225. [Google Scholar]
- Barrera, P.; Oyen, W.J.G.; Boerman, O.C.; van Riel, P.L.C.M. Scintigraphic detection of tumor necrosis factor in patients with rheumatoid arthritis. Ann. Rheum. Dis. 2003, 62, 825–828. [Google Scholar] [CrossRef]
- D’Alessandria, C.; Malviya, G.; Viscido, A.; Aratari, A.; Maccioni, F.; Amato, A.; Scopinaro, F.; Caprilli, R.; Signore, A. Use of a 99m-Technetium labelled anti-TNFa monoclonal antibody in Crohn’s Disease: In vitro and in vivo studies. Q. J. Nucl. Med. Mol. Imaging 2007, 51, 334–342. [Google Scholar]
- Conti, F.; Ceccarelli, F.; Massaro, L.; Cipriano, E.; Di Franco, M.; Alessandri, C.; Spinelli, F.R.; Scrivo, R. Biological therapies in rheumatic diseases. Clin. Ter. 2013, 164, e413–e428. [Google Scholar] [PubMed]
- Sedger, L.M.; McDermott, M.F. TNF and TNF-receptors: From mediators of cell death and inflammation to therapeutic giants—Past, present and future. Cytokine Growth Factor Rev. 2014, 25, 453–472. [Google Scholar] [CrossRef]
- Valesini, G.; Iannuccelli, C.; Marocchi, E.; Pascoli, L.; Scalzi, V.; Di Franco, M. Biological and clinical effects of anti-TNFalpha treatment. Autoimmun. Rev. 2007, 7, 35–41. [Google Scholar] [CrossRef]
- Conti, F.; Priori, R.; Chimenti, M.S.; Coari, G.; Annovazzi, A.; Valesini, G.; Signore, A. Successful treatment with intraarticular infliximab for resistant knee monarthritis in a patient with spondylarthropathy: A role for scintigraphy with 99mTc-infliximab. Arthritis Rheum. 2005, 52, 1224–1226. [Google Scholar] [CrossRef]
- Conti, F.; Malviya, G.; Ceccarelli, F.; Priori, R.; Iagnocco, A.; Valesini, G.; Signore, A. Role of scintigraphy with 99mTc-infliximab in predicting the response of intraarticular infliximab treatment in patients with refractory monoarthritis. Eur. J. Nucl. Med. Mol. Imaging 2012, 39, 1339–1347. [Google Scholar] [CrossRef]
- Roimicher, L.; Lopes, F.P.; de Souza, S.A.; Mendes, L.F.; Domingues, R.C.; da Fonseca, L.M.; Gutfilen, B. (99m)Tc-anti-TNF-α scintigraphy in RA: A comparison pilot study with MRI and clinical examination. Rheumatology 2011, 50, 2044–2050. [Google Scholar] [CrossRef] [PubMed]
- Malviya, G.; D’Alessandria, C.; Lanzolla, T.; Lenza, A.; Conti, F.; Valesini, G.; Scopinaro, F.; Dierckx, R.; Signore, A. 99mTechnetium labelled anti-TNF-α antibodies for the therapy decision-making and follow-up of patients with rheumatoid arthritis. Q. J. Nucl. Med. Mol. Imaging 2008, 52(2) (Suppl 1(2)), 13–14. [Google Scholar]
- Tran, L.; Huitema, A.D.; van Rijswijk, M.H.; Dinant, H.J.; Baars, J.W.; Beijnen, J.H.; Vogel, W.V. CD20 antigen imaging with 124I-rituximab PET/CT in patients with rheumatoid arthritis. Hum. Antibodies 2011, 20, 29–35. [Google Scholar] [CrossRef]
- Lambert, B.; Carron, P.; D’Asseler, Y.; Bacher, K.; Van den Bosch, F.; Elewaut, D.; Verbruggen, G.; Beyaert, R.; Dumolyn, C.; De Vos, F. 99mTc-labelled S-HYNIC certolizumab pegol in rheumatoid arthritis and spondyloarthritis patients: A biodistribution and dosimetry study. Eur. J. Nucl. Med. Mol. Imaging Res. 2016, 6, 88. [Google Scholar] [CrossRef]
- Carron, P.; Lambert, B.; Van Praet, L.; De Vos, F.; Varkas, G.; Jans, L.; Elewaut, D.; Van den Bosch, F. Scintigraphic detection of TNF-driven inflammation by radiolabelled certolizumab pegol in patients with rheumatoid arthritis and spondyloarthritis. RMD Open 2016, 2, e000265. [Google Scholar] [CrossRef]
- Vaiyanathan, A.; Patel, C.N.; Scarsbrook, A.F.; Chowdhury, F.U. FDG PET/CT in infection and inflammation-current and emerging clinical applications. Clin. Radiol. 2015, 70, 787–800. [Google Scholar] [CrossRef]
- Slart, R.H. FDG-PET/CT(A) imaging in large vessel vasculitis and polymyalgia rheumatica: Joint procedural recommendation of the EANM, SNMMI, and the PET Interest Group (PIG), and endorsed by the ASNC. Eur. J. Nucl. Med. Mol. Imaging 2018, 45, 1250–1269. [Google Scholar] [CrossRef]
- Meller, J.; Sahlmann, C.O.; Gürocak, O.; Liersch, T.; Meller, B. FDG-PET in Patients with FUO: The importance of diagnosis large vessels vasculitis. Q. J. Nucl. Med. Mol. Imaging 2009, 53, 51–63. [Google Scholar]
- Espígol-Frigolé, G.; Prieto-González, S.; Alba, M.A.; Tavera-Bahillo, I.; García-Martínez, A.; Gilabert, R.; Hernández-Rodríguez, J.; Cid, M.C. Advances in the diagnosis of large vessel vasculitis. Rheum. Dis. Clin. N. Am. 2015, 41, 125–140. [Google Scholar] [CrossRef] [PubMed]
- Versari, A.; Pipitone, N.; Casali, M.; Jamar, F.; Pazzola, G. Use of imaging techniques in Large Vessel Vasculitis and related conditions. Q. J. Nucl. Med. Mol. Imaging 2018, 62, 34–39. [Google Scholar]
- Soussan, M.; Nicolas, P.; Schramm, C.; Katsahian, S.; Pop, G.; Fain, O.; Mekinian, A. Management of large vessel vasculitis with FDG-PET: A systematic literature review and meta-analysis. Medicine 2015, 94, e622. [Google Scholar] [CrossRef]
- Barra, L.; Kanji, T.; Malette, J.; Pagnoux, C. Imaging modalities for the diagnosis and disease activity assessment of Takayasu’s arteritis: A systematic review and meta-analysis. Autoimm. Rev. 2018, 17, 175–187. [Google Scholar] [CrossRef] [PubMed]
- Gotthardt, M.; Bleeker-Rovers, C.P.; Boerman, O.C.; Oyen, W.J.G. Imaging of Inflammation by PET, Conventional Scintigraphy, and Other Imaging Techniques. J. Nucl. Med. 2010, 51, 1937–1949. [Google Scholar] [CrossRef]
- Puppo, C.; Massollo, M.; Paparo, F.; Camellino, D.; Piccardo, A.; Naseri, M.S.Z.; Villavecchia, G.; Rollandi, G.A.; Cimmino, M.A. Giant cell arteritis: A systematic review of the qualitative and semiquantitative methods to assess vasculitis with 18F-fluoro-deoxyglucose positron emission tomography. Biomed. Res. Int. 2014, 2014, 574248. [Google Scholar] [CrossRef]
- Prieto-González, S.; Espígol-Frigolé, G.; García-Martínez, A.; Alba, M.A.; Tavera-Bahillo, I.; Hernández-Rodríguez, J.; Renú, A.; Gilabert, R.; Lomeña, F.; Cid, M.C. The Epanding Role of Imaging in Systemic Vasculitis. Rheum. Dis. Clin. N. Am. 2016, 42, 733–751. [Google Scholar] [CrossRef]
- Meller, J.; Strutz, F.; Siefker, U.; Scheel, A.; Sahlmann, C.O.; Lehmann, K.; Conrad, M.; Vosshenrich, R. Early diagnosis and follow-up of aortitis with [(18)F]FDG PET and MRI. Eur. J. Nucl. Med. Mol. Imaging 2003, 30, 730–736. [Google Scholar] [CrossRef]
- Blockmans, D.; de Ceuninck, L.; Vanderschueren, S.; Knockaert, D.; Mortelmans, L.; Bobbaers, H. Repetitive 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: A prospective study of 35 patients. Arthritis Rheum. 2006, 55, 131–137. [Google Scholar] [CrossRef]
- Soriano, A.; Pazzola, G.; Boiardi, L.; Casali, M.; Muratore, F.; Pipitone, N.; Catanoso, M.; Aldigeri, R.; Cimino, L.; Versari, A.; et al. Distribution patterns of 18F-fluorodeoxyglucose in large vessels of Takayasu’s and giant cell arteritis using positron emission tomography. Clin. Exp. Rheumatol. 2018, 36, S99–S106. [Google Scholar]
- Muratore, F.; Crescentini, F.; Spaggiari, L.; Pazzola, G.; Casali, M.; Boiardi, L.; Pipitone, N.; Croci, S.; Galli, E.; Aldigeri, R.; et al. Aortic dilatation in patients with large vessel vasculitis: A longitudinal case control study using PET/CT. Semin. Arthritis Rheum. 2018, 47. [Google Scholar] [CrossRef]
- Olthof, S.C.; Krumm, P.; Henes, J.; Nikolaou, K.; la Fougère, C.; Pfannenberg, C.; Schwenzer, N. Imaging giant cell arteritis and Aortitis in contrast enhanced 18F-FDG PET/ CT: Which imaging score correlates best with laboratory inflammation markers? Eur. J. Radiol. 2018, 99, 94–102. [Google Scholar] [CrossRef]
- Lehmann, P.; Buchtala, S.; Achajew, N.; Haerle, P.; Ehrenstein, B.; Lighvani, H.; Fleck, M.; Marienhagen, J. 18F-FDG PET as a diagnostic procedure in large vessel vasculitis-a controlled, blinded re-examination of routine PET scans. Clin. Rheumatol. 2011, 30, 37–42. [Google Scholar] [CrossRef] [PubMed]
- Besson, F.L.; de Boysson, H.; Parienti, J.; Bouvard, G.; Bienvenu, B.; Agostini, D. Towards an optimal semiquantitative approach in giant cell arteritis: An 18F-FDG PET/CT case-control study. Eur. J. Nucl. Med. Mol. Imaging 2013, 41, 155–166. [Google Scholar] [CrossRef]
- Fuchs, M.; Briel, M.; Daikeler, T.; Walker, U.A.; Rasch, H.; Berg, S.; Ng, Q.K.; Raatz, H.; Jayne, D.; Kötter, I.; et al. The impact of 18F-FDG PET on the management of patients with suspected large vessel vasculitis. Eur. J. Nucl. Med. Mol. Imaging 2012, 39, 344–353. [Google Scholar] [CrossRef]
- Einspieler, I.; Thürmel, K.; Pyka, T.; Eiber, M.; Wolfram, S.; Moog, P.; Reeps, C.; Essler, M. Imaging large vessel vasculitis with fully integrated PET/MRI: A pilot study. Eur. J. Nucl. Med. Mol. Imaging 2015, 42, 1012–1024. [Google Scholar] [CrossRef]
- Bertagna, F.; Bosio, G.; Caobelli, F.; Motta, F.; Biasiotto, G.; Giubbini, R. Role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography for therapy evaluation of patients with large-vessel vasculitis. Jpn. J. Radiol. 2010, 28, 199–204. [Google Scholar] [CrossRef] [PubMed]
- De Boysson, H.; Aide, N.; Liozon, E.; Lambert, M.; Parienti, J.J.; Monteil, J.; Huglo, D.; Bienvenu, B.; Manrique, A.; Aouba, A. Repetitive 18F-FDG-PET/CT in patients with large-vessel giant-cell arteritis and controlled disease. Eur. J. Intern. Med. 2017, 46, 66–70. [Google Scholar] [CrossRef] [PubMed]
- Martìnez-Rodrìguez, I.; Jiménez-Alonso, M.; Quirce, R.; Jiménez-Bonilla, J.; Martìnez-Amador, N.; De Arcocha-Torres, M.; Loricera, J.; Blanco, R.; González-Gay, M.Á.; Banzo, I. 18F-FDG PET/CT in the follow-up of large-vessel vasculitis: A study of 37 consecutive patients. Semin. Arthritis Rheum. 2018, 47, 530–537. [Google Scholar] [CrossRef] [PubMed]
- Direskeneli, H. Clinical assessment in Takayasu’s arteritis: Major challenges and controversies. Clin. Exp. Rheumatol. 2017, 103, 189–193. [Google Scholar]
- Karunanithi, S.; Sharma, P.; Bal, C.; Kumar, R. (18)F-FDG PET/CT for diagnosis and treatment response evaluation in large vessel vasculitis. Eur. J. Nucl. Med. Mol. Imaging 2014, 41, 586–587. [Google Scholar] [CrossRef]
- Muto, G.; Yamashita, H.; Takahashi, Y.; Miyata, Y.; Morooka, M.; Minamimoto, R.; Kubota, K.; Kaneko, H.; Kano, T.; Mimori, A. Large vessel vasculitis in elderly patients: Early diagnosis and steroid-response evaluation with FDG-PET/CT and contrast-enhanced CT. Rheumatol. Int. 2014, 34, 1545–1554. [Google Scholar] [CrossRef]
- Henes, J.C.; Mueller, M.; Pfannenberg, C.; Kanz, L.; Koetter, I. Cyclophosphamide for large vessel vasculitis: Assessment of response by PET/CT. Clin. Exp. Rheumatol. 2011, 29, S43–S48. [Google Scholar]
- Salvarani, C.; Magnani, L.; Catanoso, M.; Pipitone, N.; Versari, A.; Dardani, L.; Pulsatelli, L.; Meliconi, R.; Boiardi, L. Tocilizumab: A novel therapy for patients with large-vessel vasculitis. Rheumatology 2012, 51, 151–156. [Google Scholar] [CrossRef]
- Wenter, V.; Sommer, N.N.; Kooijman, H.; Maurus, S.; Treitl, M.; Czihal, M.; Dechant, C.; Unterrainer, M.; Albert, N.L.; Treitl, K.M. Clinical value of [18F]FDG-PET/CT and 3D-black-blood 3T-MRI for the diagnosis of large vessel vasculitis and single-organ vasculitis of the aorta. Q. J. Nucl. Med. Mol. Imaging 2018, 62. [Google Scholar] [CrossRef]
- Sounni, N.E.; Noel, A. Targeting the Tumor Microenvironment for Cancer Therapy. Clin. Chem. 2013, 59, 85–93. [Google Scholar] [CrossRef]
- Couzin-Frankel, J. Breakthrough of the year 2013. Cancer immunotherapy. Science 2013, 342, 1432–1433. [Google Scholar] [CrossRef]
- Guldbrandsen, K.F.; Hendel, H.W.; Langer, S.W.; Fischer, B.M. Nuclear Molecular Imaging Strategies in Immune Checkpoint Inhibitor Therapy. Diagnostic 2017, 7, 23. [Google Scholar] [CrossRef]
- Evangelista, L.; de Jong, M.; del Vecchio, S.; Cai, W. The new era of cancer immunotherapy: What can molecular imaging do the help? Clin. Transl. Imaging 2017, 5, 299–301. [Google Scholar] [CrossRef]
- Zappa, C.; Mousa, S.A. Non-small cell lung cancer: Current treatment and future advances. Transl. Lung Cancer Res. 2016, 5, 288–300. [Google Scholar] [CrossRef]
- Kazandjian, D.; Suzman, D.L.; Blumenthal, G.; Mushti, S.; He, K.; Libeg, M.; Keegan, P.; Pazdur, R. FDA Approval Summary: Nivolumab for the treatment of metastatic non-small cell lung cancer with progression on or after platinum-based chemotherapy. Oncologist 2016, 21, 634–642. [Google Scholar] [CrossRef]
- Rizvi, N.A.; Garon, E.B.; Patnaik, A.; Gandhi, L.; Leighl, N.B.; Balmanoukian, A.S.; Goldman, J.W.; Eder, J.P.; Johnson, E.; Blumenschein, G.R.; et al. Safety and clinical activity of MK-3475 as initial therapy in patients with advanced non-small cell lung cancer (NSCLC). J. Clin. Oncol. 2014, 32, 8007. [Google Scholar] [CrossRef]
- Signore, A.; Annovazzi, A.; Barone, R.; Bonanno, E.; D’Alessandria, C.; Chianelli, M.; Mather, S.J.; Bottoni, U.; Panetta, C.; Innocenzi, D.; et al. 99mTc-interleukin-2 scintigraphy as a potential tool for evaluating tumor-infiltrating lymphocytes in melanoma lesions: A validation study. J. Nucl. Med. 2004, 45, 1647–1652. [Google Scholar]
- Loose, D.; Signore, A.; Staelens, L.; Bulcke, K.V.; Vermeersch, H.; Dierckx, R.A.; Bonanno, E.; Van de Wiele, C. (123)I-Interleukin-2 uptake in squamous cell carcinoma of the head and neck carcinoma. Eur. J. Nucl. Med. Mol. Imaging 2008, 35, 281–286. [Google Scholar] [CrossRef]
- Renard, V.; Staelens, L.; Signore, A.; Van Belle, S.; Dierckx, R.A.; Van De Wiele, C. Iodine-123-interleukin-2 scintigraphy in metastatic hypernephroma: A pilot study. Q. J. Nucl. Med. Mol. Imaging 2007, 51, 352–356. [Google Scholar]
- Zeelen, C.; Paus, C.; Draper, D.; Heskamp, S.; Signore, A.; Galli, F.; Griessinger, C.M.; Aarntzen, E.H. In vivo imaging of tumor-infiltrating immune cells: Implications for cancer immunotherapy. Q. J. Nucl. Med. Mol. Imaging 2018, 62, 56–77. [Google Scholar]
- Natarajan, A.; Mayer, A.T.; Xu, L.; Reeves, R.E.; Gano, J.; Gambhir, S.S. Novel Radiotracer for ImmunoPET Imaging of PD-1 Checkpoint Expression on Tumor Infiltrating Lymphocytes. Bioconjugate Chem. 2015, 26, 2062–2069. [Google Scholar] [CrossRef] [PubMed]
- Hettich, M.; Braun, F.; Bartholoma, M.D.; Schirmbeck, R.; Niedermann, G. High-Resolution PET Imaging with Therapeutic Antibody-based PD-1/PD-L1 Checkpoint Tracers. Theranostics 2016, 6, 1629–1640. [Google Scholar] [CrossRef]
- Natarajan, A.; Mayer, A.T.; Reeves, R.E.; Nagamine, C.M.; Gambhir, S.S. Development of Novel ImmunoPET Tracers to Image Human PD-1 Checkpoint Expression on Tumor-Infiltrating Lymphocytes in a Humanized Mouse Model. Mol. Imaging Biol. 2017, 19, 903–914. [Google Scholar] [CrossRef] [PubMed]
- England, C.G.; Jiang, D.; Ehlerding, E.B.; Rekoske, B.T.; Ellison, P.A.; Hernandez, R.; Barnhart, T.E.; McNeel, D.G.; Huang, P.; Cai, W. 89Zr-labeled nivolumab for imaging of T-cell infiltration in a humanized murine model of lung cancer. Eur. J. Nucl. Med. Mol. Imaging 2018, 45, 110–120. [Google Scholar] [CrossRef] [PubMed]
- Cole, E.L.; Kim, J.; Donnelly, D.J.; Smith, R.A.; Cohen, D.; Lafont, V.; Morin, P.E.; Huang, R.Y.; Chow, P.L.; Hayes, W.; et al. Radiosynthesis and preclinical PET evaluation of 89Zr-nivolumab (BMS-936558) in healthy non-human primates. Bioorg. Med. Chem. 2017, 25, 5407–5414. [Google Scholar] [CrossRef]
- England, C.G.; Ehlerding, E.B.; Hernandez, R.; Rekoske, B.T.; Graves, S.A.; Sun, H.; Liu, G.; McNeel, D.G.; Barnhart, T.E.; Cai, W. Preclinical Pharmacokinetics and Biodistribution Studies of 89Zr-Labeled Pembrolizumab. J. Nucl. Med. 2017, 58, 162–168. [Google Scholar] [CrossRef]
- Natarajan, A.; Patel, C.B.; Habte, F.; Gambhir, S.S. Dosimetry Prediction for Clinical Translation of 64Cu-Pembrolizumab ImmunoPET Targeting Human PD-1 Expression. Sci. Rep. 2018, 8, 633. [Google Scholar] [CrossRef]
- Chatterjee, S.; Lesniak, W.G.; Gabrielson, M.; Lisok, A.; Wharram, B.; Sysa-Shah, P.; Azad, B.B.; Pomper, M.G.; Nimmagadda, S. A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors. Oncotarget 2016, 7, 10215–10227. [Google Scholar] [CrossRef]
- Lesniak, W.G.; Chatterjee, S.; Gabrielson, M.; Lisok, A.; Wharram, B.; Pomper, M.G.; Nimmagadda, S. PD-L1 Detection in Tumors Using [(64)Cu]Atezolizumab with PET. Bioconjugate Chem. 2016, 27, 2103–2110. [Google Scholar] [CrossRef]
- Bensch, F.; van der Veen, E.; Jorritsma, A.; Lub-de Hooge, M.; Boellaard, R.; Oosting, S.; Schroder, C.; Hiltermann, J.; van der Wekken, A.; Groen, H.; et al. First-in-human PET imaging with the PD-L1 antibody 89Zr-atezolizumab. Cancer Res. 2017, 77. [Google Scholar] [CrossRef]
- Chatterjee, S.; Lesniak, W.G.; Nimmagadda, S. Noninvasive Imaging of Immune Checkpoint Ligand PD-L1 in Tumors and Metastases for Guiding Immunotherapy. Mol. Imaging 2017, 16, 1536012117718459. [Google Scholar] [CrossRef]
- Nedrow, J.R.; Josefsson, A.; Park, S.; Ranka, S.; Roy, S.; Sgouros, G. Imaging of Programmed Cell Death Ligand 1: Impact of Protein Concentration on Distribution of Anti-PD-L1 SPECT Agents in an Immunocompetent Murine Model of Melanoma. J. Nucl. Med. 2017, 58, 1560–1566. [Google Scholar] [CrossRef]
- Kikuchi, M.; Clump, D.A.; Srivastava, R.M.; Sun, L.; Zeng, D.; Diaz-Perez, J.A.; Anderson, C.J.; Edwards, W.B.; Ferris, R.L. Preclinical immunoPET/CT imaging using Zr-89-labeled anti-PD-L1 monoclonal antibody for assessing radiation-induced PD-L1 upregulation in head and neck cancer and melanoma. Oncoimmunology 2017, 6, e1329071. [Google Scholar] [CrossRef]
- Heskamp, S.; Hobo, W.; Molkenboer-Kuenen, J.D.; Olive, D.; Oyen, W.J.; Dolstra, H.; Boerman, O.C. Noninvasive Imaging of Tumor PD-L1 Expression Using Radiolabeled Anti-PD-L1 Antibodies. Cancer Res. 2015, 75, 2928–2936. [Google Scholar] [CrossRef]
- Bensch, F.; van der Veen, E.L.; Lub-de Hooge, M.N.; Jorritsma-Smit, A.; Boellaard, R.; Kok, I.C.; Oosting, S.F.; Schröder, C.P.; Hiltermann, T.J.N.; van der Wekken, A.J.; et al. 89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer. Nat. Med. 2018, 24, 1852–1858. [Google Scholar] [CrossRef]
- Mayer, A.T.; Natarajan, A.; Gordon, S.R.; Maute, R.L.; McCracken, M.N.; Ring, A.M.; Weissman, I.L.; Gambhir, S.S. Practical Immuno-PET Radiotracer Design Considerations for Human Immune Checkpoint Imaging. J. Nucl. Med. 2017, 58, 538–546. [Google Scholar] [CrossRef]
- Gonzàlez Trotter, D.E.; Meng, X.; McQuade, P.; Rubins, D.; Klimas, M.; Zeng, Z.; Connolly, B.M.; Miller, P.J.; O’Malley, S.S.; Lin, S.A.; et al. In Vivo Imaging of the Programmed Death Ligand 1 by 18F PET. J. Nucl. Med. 2017, 58, 1852–1857. [Google Scholar] [CrossRef]
- Truillet, C.; Oh, H.L.J.; Yeo, S.P.; Lee, C.; Huynh, L.T.; Wei, J.; Parker, M.F.L.; Blakely, C.; Sevillano, N.; Wang, Y.; et al. Imaging PD-L1 Expression with ImmunoPET. Bioconjugate Chem. 2018, 29, 96–103. [Google Scholar] [CrossRef]
- Higashikawa, K.; Yagi, K.; Watanabe, K.; Kamino, S.; Ueda, M.; Hiromura, M.; Enomoto, S. 64Cu-DOTA-anti-CTLA-4 mAb enabled PET visualization of CTLA-4 on the T-cell infiltrating tumor tissues. PLoS ONE 2014, 9, e109866. [Google Scholar] [CrossRef]
- Rashidian, M.; Ingram, J.R.; Dougan, M.; Dongre, A.; Whang, K.A.; LeGall, C.; Cragnolini, J.J.; Bierie, B.; Gostissa, M.; Gorman, J.; et al. Predicting the response to CTLA-4 blockade by longitudinal noninvasive monitoring of CD8 T cells. J. Exp. Med. 2017, 214, 2243–2255. [Google Scholar] [CrossRef]
- Robb, R.J.; Mayer, P.C.; Garlick, R. Retention of biological activity following radioiodination of human interleukin 2: Comparison with biosynthetically labeled growth factor in receptor binding assays. J. Immunol. Methods 1985, 81, 15–30. [Google Scholar] [CrossRef]
- Gennuso, R.; Spigelman, M.K.; Vallabhajosula, S.; Moore, F.; Zappulla, R.A.; Nieves, J.; Strauchen, J.A.; Paciucci, P.A.; Malis, L.I.; Goldsmith, S.J.; et al. Systemic biodistribution of radioiodinated interleukin-2 in the rat. J. Biol. Response Mod. 1989, 8, 375–384. [Google Scholar]
- Koths, K.; Halenbech, R. Pharmacokinetic studies on 35S-labeled recombinant interleukin-2 in mice. In Cellular and Molecular Biology of Lymphokines; Sorg, C., Schimpl, A., Eds.; Academic Press Inc: Orlando, FL, USA, 1985; pp. 779–783. [Google Scholar]
- Signore, A.; Beverley, P.C.; Parman, A.; Negri, M.; Pozzilli, P. Labelling of interleukin-2 (IL-2) with 123-iodine with retention of its capacity to bind to activated lymphocytes. Exp. Clin. Endocrinol. 1987, 89, 301–306. [Google Scholar] [CrossRef]
- Signore, A.; Parman, A.; Pozzilli, P.; Andreani, D.; Beverley, P.C. Detection of activated lymphocytes in endocrine pancreas of BB/W rats by injection of 123I-interleukin-2: An early sign of type 1 diabetes. Lancet 1987, 2, 537–540. [Google Scholar] [CrossRef]
- Signore, A.; Chianelli, M.; Ferretti, E.; Toscano, A.; Britton, K.E.; Andreani, D.; Gale, E.A.; Pozzilli, P. New approach for in vivo detection of insulitis in type I diabetes: Activated lymphocyte targeting with 123I-labelled interleukin 2. Eur. J. Endocrinol. 1994, 131, 431–437. [Google Scholar] [CrossRef]
- Rolandsson, O.; Stigbrand, T.; Riklundåhlström, K.; Eary, J.; Greenbaum, C. Accumulation of (125)iodine labeled interleukin-2 in the pancreas of NOD mice. J. Autoimmun. 2001, 17, 281–287. [Google Scholar] [CrossRef]
- Abbs, I.C.; Pratt, J.R.; Dallman, M.J.; Sacks, S.H. Analysis of activated T cell infiltrates in rat renal allografts by gamma camera imaging after injection of 123iodine-interleukin 2. Transpl. Immunol. 1993, 1, 45–51. [Google Scholar] [CrossRef]
- Signore, A.; Chianelli, M.; Annovazzi, A.; Rossi, M.; Maiuri, L.; Greco, M.; Ronga, G.; Britton, K.E.; Picarelli, A. Imaging active lymphocytic infiltration in coeliac disease with iodine-123-interleukin-2 and the response to diet. Eur. J. Nucl. Med. Mol. Imaging 2000, 27, 18–24. [Google Scholar] [CrossRef]
- Signore, A.; Chianelli, M.; Annovazzi, A.; Bonanno, E.; Spagnoli, L.G.; Pozzilli, P.; Pallone, F.; Biancone, L. 123I-interleukin-2 scintigraphy for in vivo assessment of intestinal mononuclear cell infiltration in Crohn’s disease. J. Nucl. Med. 2000, 41, 242–249. [Google Scholar]
- Signore, A.; Picarelli, A.; Annovazzi, A.; Britton, K.E.; Grossman, A.B.; Bonanno, E.; Maras, B.; Barra, D.; Pozzilli, P. 123I-Interleukin-2: Biochemical characterization and in vivo use for imaging autoimmune diseases. Nucl. Med. Commun. 2003, 24, 305–316. [Google Scholar] [CrossRef]
- Chianelli, M.; Signore, A.; Fritzberg, A.R.; Mather, S.J. The development of technetium-99m-labelled interleukin-2: A new radiopharmaceutical for the in vivo detection of mononuclear cell infiltrates in immune-mediated diseases. Nucl. Med. Biol. 1997, 24, 579–586. [Google Scholar] [CrossRef]
- Chianelli, M.; Mather, S.J.; Grossman, A.; Sobnak, R.; Fritzberg, A.; Britton, K.E.; Signore, A. 99mTc-interleukin-2 scintigraphy in normal subjects and in patients with autoimmune thyroid diseases: A feasibility study. Eur. J. Nucl. Med. Mol. Imaging 2008, 35, 2286–2293. [Google Scholar] [CrossRef]
- Annovazzi, A.; Bonanno, E.; Arca, M.; D’Alessandria, C.; Marcoccia, A.; Spagnoli, L.G.; Violi, F.; Scopinaro, F.; De Toma, G.; Signore, A. 99mTc-interleukin-2 scintigraphy for the in vivo imaging of vulnerable atherosclerotic plaques. Eur. J. Nucl. Med. Mol. Imaging 2006, 33, 117–126. [Google Scholar] [CrossRef]
- Hubalewska-Dydejczyk, A.; Stompór, T.; Kalembkiewicz, M.; Krzanowski, M.; Mikolajczak, R.; Sowa-Staszczak, A.; Tabor-Ciepiela, B.; Karczmarczyk, U.; Kusnierz-Cabala, B.; Sulowicz, W. Identification of inflamed atherosclerotic plaque using 123 I-labeled interleukin-2 scintigraphy in high-risk peritoneal dialysis patients: A pilot study. Perit. Dial. Int. 2009, 29, 568–574. [Google Scholar]
- Di Gialleonardo, V.; Signore, A.; Willemsen, A.T.; Sijbesma, J.W.; Dierckx, R.A.; de Vries, E.F. Pharmacokinetic modelling of N-(4-[(18)F]fluorobenzoyl)interleukin-2 binding to activated lymphocytes in an xenograft model of inflammation. Eur. J. Nucl. Med. Mol. Imaging 2012, 39, 1551–1560. [Google Scholar] [CrossRef]
- Hartimath, S.V.; Draghiciu, O.; van de Wall, S.; Manuelli, V.; Dierckx, R.A.J.O.; Nijman, H.W.; Daemen, T.; de Vries, E.F.J. Noninvasive monitoring of cancer therapy induced activated T cells using [18F]FB-IL-2 PET imaging. Oncoimmunology 2017, 6, e1248014. [Google Scholar] [CrossRef]
- Hartimath, S.V.; Manuelli, V.; Zijlma, R.; Signore, A.; Nayak, T.K.; Freimoser-Grundschober, A.; Klein, C.; Dierckx, R.A.J.O.; de Vries, E.F.J. Pharmacokinetic properties of radiolabeled mutant Interleukin-2v: A PET imaging study. Oncotarget 2018, 9, 7162–7174. [Google Scholar] [CrossRef]
- Markovic SNGalli, F.; Suman, V.J.; Nevala, W.K.; Paulsen, A.M.; Hung, J.C.; Gansen, D.N.; Erickson, L.A.; Marchetti, P.; Wiseman, G.A.; Signore, A. Non-invasive visualization of tumor infiltrating lymphocytes in patients with metastatic melanoma undergoing immune checkpoint inhibitor therapy: A pilot study. Oncotarget 2018, 9, 30268–30278. [Google Scholar] [CrossRef]
- Grimaldi, S.; Terroir, M.; Caramella, C. Advances in oncological treatment: Limitations of RECIST 1.1 criteria. Q. J. Nucl. Med. Mol. Imaging 2018, 62, 129–139. [Google Scholar] [PubMed]
- Tarhini, A.A. Tremelimumab: A review of development date in solid tumors. Immunotherapy 2013, 5, 215–229. [Google Scholar] [CrossRef]
- Hoos, A.; Parmiani, G.; Hege, K.; Sznol, M.; Loibner, H.; Eggermont, A.; Urba, W.; Blumenstein, B.; Sacks, N.; Keilholz, U.; et al. Cancer Vaccine Clinical Trial Working Group. A clinical development paradigm for cancer vaccines and related biologics. J. Immunother. 2007, 30, 1–15. [Google Scholar] [CrossRef] [PubMed]
- Seymour, L.; Bogaerts, J.; Perrone, A.; Ford, R.; Schwartz, L.H.; Mandrekar, S.; Lin, N.U.; Litière, S.; Dancey, J.; Chen, A.; et al. RECIST working group. iRECIST: Guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017, 18, e143–e152. [Google Scholar] [CrossRef]
- Bier, G.; Hoffmann, V.; Kloth, C.; Othman, A.E.; Eigentler, T.; Garbe, C.; La Fougère, C.; Pfannenberg, C.; Nikolaou, K.; Klumpp, B. CT imaging of bone and bone marrow infiltration in malignant melanoma—Challenges and limitations for clinical staging in comparison to 18FDG-PET/CT. Eur. J. Radiol. 2016, 85, 732–738. [Google Scholar] [CrossRef]
- Kong, B.Y.; Menzies, A.M.; Saunders, C.A.; Liniker, E.; Ramanujam, S.; Guminski, A.; Kefford, R.F.; Long, G.V.; Carlino, M.S. Residual FDG-PET metabolic activity in metastatic melanoma patients with prolonged response to anti-PD-1 therapy. Pigment Cell Melanoma Res. 2016, 29, 572–577. [Google Scholar] [CrossRef]
Radiopharmaceutical | Indication | |
---|---|---|
Infectious diseases | 99mTc/(111In)-WBC | Infection |
99mTc-besilesomab (Scintimun) | Infection | |
18F-FDG | Infection, inflammation, oncology | |
99mTc-ciprofloxacin (Infecton®) | Bacterial infection | |
99mTc-ubiquicidin | Bacterial infection | |
99mTc-fluconazole | Fungal infection | |
18F-FEAU | Herpes Simplex Virus | |
Inflammatory diseases | 99mTc/123I/18F-IL2 | Inflammatory bowel disease, Sjögren Syndrome, type 1 diabetes, thyroiditis, inflammatory plaque, rheumatoid arthritis |
111In/68Ga-somatostatin analogues | Rheumatoid arthritis | |
99mTc/111In/123I-anti-TNFα MoAb (infliximab, adalimumab, golimumab, certolizumab pegol, etanercept) | Rheumatoid arthritis | |
99mTc/111In/89Zr-rituximab® | Rheumatoid arthritis | |
Tumour environment | 99mTc/111In/89Zr-bevacizumab | Breast cancer, renal cell carcinoma |
99mTc/123I/18F-IL2 | Melanoma, squamous cell carcinoma of head and neck, renal cell carcinoma | |
111In/89Zr/64Cu-PD1/PDL-1 MoAb (pembrolizumab, nivolumab, atezolizumab) | Metastatic lung cancer, bladder cancer, urothelial carcinoma, melanoma | |
18F/89Zr/64Cu-CTLA-4 MoAbs (ipilimumab, tremelimumab) | Melanoma, colon cancer |
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Signore, A.; Lauri, C.; Auletta, S.; Anzola, K.; Galli, F.; Casali, M.; Versari, A.; Glaudemans, A.W.J.M. Immuno-Imaging to Predict Treatment Response in Infection, Inflammation and Oncology. J. Clin. Med. 2019, 8, 681. https://doi.org/10.3390/jcm8050681
Signore A, Lauri C, Auletta S, Anzola K, Galli F, Casali M, Versari A, Glaudemans AWJM. Immuno-Imaging to Predict Treatment Response in Infection, Inflammation and Oncology. Journal of Clinical Medicine. 2019; 8(5):681. https://doi.org/10.3390/jcm8050681
Chicago/Turabian StyleSignore, Alberto, Chiara Lauri, Sveva Auletta, Kelly Anzola, Filippo Galli, Massimiliano Casali, Annibale Versari, and Andor W.J.M. Glaudemans. 2019. "Immuno-Imaging to Predict Treatment Response in Infection, Inflammation and Oncology" Journal of Clinical Medicine 8, no. 5: 681. https://doi.org/10.3390/jcm8050681